Table 3.

Multivariable Adjusted Analyses for Week 8 Comparing RBL and Placebo Treatment^a

Cdiff32 Domain	Difference in Cdiff32 Score, Point Estimateb (95% CI) (n = 185c)	P Value
Total	7.2 (1.2–13.2)	<.05
Physical	6.6 (.8–12.3)	<.05
Mental	8.3 (1.4–15.3)	<.05
Social	6.5 (−.6 to 13.6)	.08

Abbreviations: Cdiff32, Clostridioides difficile Health-related Quality-of-Life Survey; CI, confidence interval; RBL, fecal microbiota, live-jslm (REBYOTA; Rebiotix).

^aThe analyses included the following baseline covariates: respective baseline Cdiff32 score, treatment group, sex, age (in years), number of C difficile episodes before treatment, treatment with fidaxomicin, proton pump inhibitor use, metabolism and nutrition disorders, surgical and medical procedures, infections and infestations, gastrointestinal disorders, and psychiatric disorders.

^bThe point estimates represent improvement in Cdiff32 total or domain score in patients given RBL versus placebo.

^cSample sizes for the as-observed analysis differed across domain scores according to data availability.